- Home
- WRD vs ZBIO Comparison
WRD vs ZBIO Comparison
Compare WRD & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRD
- ZBIO
- Stock Information
- Founded
- WRD 2017
- ZBIO 2019
- Country
- WRD China
- ZBIO United States
- Employees
- WRD N/A
- ZBIO N/A
- Industry
- WRD
- ZBIO
- Sector
- WRD
- ZBIO
- Exchange
- WRD NYSE
- ZBIO NYSE
- Market Cap
- WRD 2.8B
- ZBIO 389.2M
- IPO Year
- WRD 2024
- ZBIO 2024
- Fundamental
- Price
- WRD $8.11
- ZBIO $9.54
- Analyst Decision
- WRD Buy
- ZBIO Strong Buy
- Analyst Count
- WRD 2
- ZBIO 7
- Target Price
- WRD $22.00
- ZBIO $32.29
- AVG Volume (30 Days)
- WRD 8.7M
- ZBIO 223.0K
- Earning Date
- WRD 08-25-2025
- ZBIO 08-16-2025
- Dividend Yield
- WRD N/A
- ZBIO N/A
- EPS Growth
- WRD N/A
- ZBIO N/A
- EPS
- WRD N/A
- ZBIO N/A
- Revenue
- WRD $49,940,881.00
- ZBIO $15,000,000.00
- Revenue This Year
- WRD N/A
- ZBIO $206.00
- Revenue Next Year
- WRD $218.93
- ZBIO $41.92
- P/E Ratio
- WRD N/A
- ZBIO N/A
- Revenue Growth
- WRD N/A
- ZBIO N/A
- 52 Week Low
- WRD $6.03
- ZBIO $5.83
- 52 Week High
- WRD $44.00
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- WRD N/A
- ZBIO N/A
- Support Level
- WRD N/A
- ZBIO N/A
- Resistance Level
- WRD N/A
- ZBIO N/A
- Average True Range (ATR)
- WRD 0.00
- ZBIO 0.00
- MACD
- WRD 0.00
- ZBIO 0.00
- Stochastic Oscillator
- WRD 0.00
- ZBIO 0.00
About WRD WERIDE INC. SPON ADS EACH REP 3 CL A ORD SHS
WeRide Inc operates in the autonomous driving industry. The company has developed a universal autonomous driving technology platform that integrates full-stack software algorithms, modularized hardware solutions, and a cloud-based infrastructure platform. The company provides autonomous driving products and services from L2 to L4 vehicles. The products of the company includes Robotaxi, Robobus, Robovan, Robosweeper, and others. The company earns its revenue from the People's Republic of China.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.